Elekta's Leksell Gamma Knife Perfexion Earns Top Rank in 2013's Best in KLAS for Radiation Therapy

ATLANTA, June 20, 2013 /PRNewswire/ -- Elekta claimed the top two rankings in the KLAS research firm's recently released 2013 Best in KLAS Awards: Medical Equipment & Infrastructure report*. Elekta's Leksell Gamma Knife® Perfexion radiosurgery system and Elekta Infinity radiation therapy system earned the #1 and #2 rankings, respectively. This is the second consecutive year in which Perfexion has won the Best in KLAS award for radiation therapy.

In the report, Perfexion scored 92.9 out of 100, and 96 percent of customers indicated they would buy again. On a 1 to 9 scale, Perfexion received an 8.7 from respondents for satisfaction with product uptime, the highest score among all vendors rated in the market segment.

"Year after year, Leksell Gamma Knife Perfexion is consistently rated as one of the very best solutions in radiation therapy by KLAS respondents," says Jay Hoey, Executive Vice President, Elekta North America. "We are honored by this recognition from our customers and it inspires us to continue refining this product and our entire range of solutions."

KLAS surveys include opinions of thousands of health care professionalsThe KLAS awards are based on data from customer surveys of hospital and clinic executives, administrators, physicians, nurses and other directors and managers interacting with health care equipment and infrastructure solutions.

According to KLAS, Best in KLAS designations go to solutions that have excelled in their respective market segments, that show the vendor's leadership in working with customers to resolve issues and match expectations to reality, and that have the broadest operational and clinical impact to health care organizations.

"We're seeing real movement in the market," says Kent Gale, KLAS founder and VP of medical imaging and equipment. "It's a strong indicator of the increasing competitiveness of the vendors as they strive to improve their offerings. And that will ultimately benefit the providers and their patients."

About LeksellGamma KnifeLeksell Gamma Knife® is a dedicated, fully integrated system for brain radiosurgery. Gamma Knife radiosurgery is performed in hundreds of leading hospitals and clinics around the world, and more than 70,000 patients are treated every year. Leksell Gamma Knife has an unmatched scientific track record, and has been documented in more than 3,000 peer-reviewed articles.

About ElektaElekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

About KLASKLAS is a research firm on a global mission to improve healthcare delivery by enabling providers to be heard and to be counted. Working with thousands of healthcare executives and clinicians, KLAS gathers data on software, services, medical equipment, and infrastructure systems to deliver timely reports, trends, and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance. KLAS was founded in 1996, and their staff and advisory board members average 25 years of healthcare information technology experience. For more information, go to www.KLASresearch.com, email marketing@KLASresearch.com, or call 1-800-920-4109 to speak with a KLAS representative. Follow KLAS on Twitter @KLASresearch.